Verici Dx to Supply Tests for Kidney Transplant Therapy Trial

05:29 AM EDT, 10/22/2026 (MT Newswires) -- Verici Dx (VRCI.L) received an order from Asahi Kasei Therapeutics to provide biomarker testing for a phase 2 clinical trial evaluating an investigational therapy meant to prevent organ rejection in kidney transplant patients. The clinical diagnostics company will provide blood-based testing, including its pre-transplant risk assessment assay, as an exploratory research tool for the trial evaluating pegrizeprument, according to a Thursday release.